JPWO2022020105A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022020105A5 JPWO2022020105A5 JP2023504620A JP2023504620A JPWO2022020105A5 JP WO2022020105 A5 JPWO2022020105 A5 JP WO2022020105A5 JP 2023504620 A JP2023504620 A JP 2023504620A JP 2023504620 A JP2023504620 A JP 2023504620A JP WO2022020105 A5 JPWO2022020105 A5 JP WO2022020105A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- complex
- conjugate
- composition
- molecular payload
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055721P | 2020-07-23 | 2020-07-23 | |
| US63/055,721 | 2020-07-23 | ||
| US202063069071P | 2020-08-23 | 2020-08-23 | |
| US63/069,071 | 2020-08-23 | ||
| US202163143825P | 2021-01-30 | 2021-01-30 | |
| US63/143,825 | 2021-01-30 | ||
| PCT/US2021/040984 WO2022020105A1 (en) | 2020-07-23 | 2021-07-09 | Anti-transferrin receptor (tfr) antibody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535443A JP2023535443A (ja) | 2023-08-17 |
| JPWO2022020105A5 true JPWO2022020105A5 (enExample) | 2024-07-17 |
Family
ID=79729848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504620A Pending JP2023535443A (ja) | 2020-07-23 | 2021-07-09 | 抗トランスフェリン受容体（ＴｆＲ）抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230256112A1 (enExample) |
| EP (1) | EP4185315A4 (enExample) |
| JP (1) | JP2023535443A (enExample) |
| KR (1) | KR20230041760A (enExample) |
| CN (1) | CN116348138A (enExample) |
| AU (1) | AU2021312708A1 (enExample) |
| BR (1) | BR112023001005A2 (enExample) |
| CA (1) | CA3186727A1 (enExample) |
| IL (1) | IL299667A (enExample) |
| MX (1) | MX2023000962A (enExample) |
| WO (1) | WO2022020105A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| BR112023001125A2 (pt) * | 2020-07-23 | 2023-02-14 | Dyne Therapeutics Inc | Complexos de direcionamento muscular e usos dos mesmos para tratar distrofinopatias |
| CA3186755A1 (en) * | 2020-07-23 | 2022-01-27 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2024000489A (es) | 2021-07-09 | 2024-04-09 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y formulaciones para el tratamiento de las distrofinopatías. |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| KR20240107202A (ko) | 2021-09-01 | 2024-07-08 | 바이오젠 엠에이 인코포레이티드 | 항-트랜스페린 수용체 항체 및 이의 용도 |
| CA3255934A1 (en) | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | MUSCLE TARGETTING COMPLEXES AND FORMULATIONS FOR THE TREATMENT OF MYOTONIC DYSTROPHY |
| WO2024026474A1 (en) * | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
| WO2024064753A1 (en) * | 2022-09-20 | 2024-03-28 | Dana-Farber Cancer Institute, Inc. | Reversible control of chimeric antigen receptor t cells |
| WO2025024334A1 (en) | 2023-07-21 | 2025-01-30 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
| CN119192378B (zh) * | 2024-10-16 | 2025-10-17 | 中国人民解放军军事科学院军事医学研究院 | 一种pH敏感型人源抗转铁蛋白受体1抗体 |
| CN119161483A (zh) * | 2024-10-16 | 2024-12-20 | 中国人民解放军军事科学院军事医学研究院 | 人源抗转铁蛋白受体1抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130164A2 (en) * | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
| HRP20240107T1 (hr) * | 2013-05-20 | 2024-04-12 | F. Hoffmann - La Roche Ag | Protutijela na transferinski receptor i postupci uporabe |
| MY187033A (en) * | 2015-06-24 | 2021-08-27 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210324101A1 (en) * | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| EP3829635A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF MUSCLE ATROPHY |
| IL319265A (en) * | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
-
2021
- 2021-07-09 IL IL299667A patent/IL299667A/en unknown
- 2021-07-09 US US18/017,167 patent/US20230256112A1/en active Pending
- 2021-07-09 JP JP2023504620A patent/JP2023535443A/ja active Pending
- 2021-07-09 CA CA3186727A patent/CA3186727A1/en active Pending
- 2021-07-09 KR KR1020237005829A patent/KR20230041760A/ko active Pending
- 2021-07-09 MX MX2023000962A patent/MX2023000962A/es unknown
- 2021-07-09 EP EP21846109.3A patent/EP4185315A4/en active Pending
- 2021-07-09 BR BR112023001005A patent/BR112023001005A2/pt unknown
- 2021-07-09 AU AU2021312708A patent/AU2021312708A1/en active Pending
- 2021-07-09 WO PCT/US2021/040984 patent/WO2022020105A1/en not_active Ceased
- 2021-07-09 CN CN202180064690.5A patent/CN116348138A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022020105A5 (enExample) | ||
| JP7447183B2 (ja) | 親水性抗体－薬物コンジュゲート | |
| US10758556B2 (en) | Anthracycline-based antibody drug conjugates having high in vivo tolerability | |
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JPWO2021154476A5 (enExample) | ||
| JP2008515889A5 (enExample) | ||
| JP2015526435A (ja) | 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート | |
| CN108452319A (zh) | 靶向cd20的抗体偶联药物制剂 | |
| US20110142756A1 (en) | Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Precipitates In The Cancer | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2022514348A (ja) | チオール多重リンカーを有するａｄｃ | |
| IL310175A (en) | Methods for treating non-muscle invasive bladder cancer (nmibc) with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| KR20190023084A (ko) | 이중 특이성 항체를 이용한 항체 약물 복합체 플랫폼 | |
| Shao et al. | Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C | |
| CN101277716A (zh) | 治疗癌症的抗体 | |
| US7615221B2 (en) | Compositions and methods for treating cancer | |
| US20230346969A1 (en) | Intermediate for preparing antibody-drug conjugate (adc), preparation method therefor, and use thereof | |
| CN109982720A (zh) | 抗体药物缀合物 | |
| CN114667160A (zh) | 免疫耐受的弹性蛋白样重组肽及其使用方法 | |
| Yu et al. | The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer | |
| CN119868576A (zh) | 用于制备抗体与药物偶联物的中间体及其制备方法和应用 | |
| WO2025176180A1 (zh) | 艾日布林衍生物药物偶联物用于治疗肿瘤的用途 | |
| HK40088389B (zh) | 针对folr1的双特异性抗体及其用途 | |
| HK40088389A (zh) | 针对folr1的双特异性抗体及其用途 | |
| KR20250175725A (ko) | Cd80 단백질 및 il-2 단백질을 포함하는 융합단백질 및 항체-약물 접합체를 포함하는 암 치료용 약학 조성물 |